These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19087143)

  • 1. Can we get rid of neutralizing antibodies against interferon-β?
    Buttmann M; Toyka KV
    Eur J Neurol; 2009 Jan; 16(1):7-9. PubMed ID: 19087143
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
    Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
    Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
    Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M
    Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243
    [No Abstract]   [Full Text] [Related]  

  • 5. The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies.
    Giantzi V; Karapanayiotides T; Lagoudaki R; Poulatsidou KN; Lourbopoulos A; Daniilidis M; Taskos N; Milonas I; Grigoriadis N
    Eur Neurol; 2016; 75(1-2):82-8. PubMed ID: 26867030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab.
    Sørensen PS; Koch-Henriksen N; Jensen PE
    Neurology; 2011 Feb; 76(8):759-60. PubMed ID: 21339504
    [No Abstract]   [Full Text] [Related]  

  • 7. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
    Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM
    Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT
    Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al.
    Menge T; Hartung HP; Kieseier BC
    J Neurol; 2011 May; 258(5):904-7. PubMed ID: 21340521
    [No Abstract]   [Full Text] [Related]  

  • 11. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis.
    Bendtzen K
    J Interferon Cytokine Res; 2010 Oct; 30(10):759-66. PubMed ID: 20874253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
    van Beers MM; Jiskoot W; Schellekens H
    J Interferon Cytokine Res; 2010 Oct; 30(10):767-75. PubMed ID: 20874254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
    Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
    Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The methods of detection of binding and neutralizing antibodies to preparations of interferon-beta].
    Nazarov VD; Lapin SV; Surkova EA; Makshakov GS; Mazing AV; Evdoshenko EP; Totolian AA
    Klin Lab Diagn; 2016 Oct; 61(10):710-4. PubMed ID: 30615336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
    Carlson RJ; Doucette JR; Knox K; Nazarali AJ
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R; Stürzebecher CS; Kapp JF
    Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H; Stelmasiak Z
    Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
    Romero López J; Maciñeiras Montero JL
    Med Clin (Barc); 2005 Feb; 124(4):144-5. PubMed ID: 15713245
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.